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Abstract: Idiopathic pulmonary fibrosis (IPF) is a chronic, pulmonary-limited, interstitial lung disease
with a poor prognosis. This condition is characterized by different clinical scenarios, ranging from
the most typical slow and progressive deterioration of symptoms to a rapid and abrupt decline
of lung function. Rapid worsening of clinical course is due to superimposed complications and
comorbidities that can develop in IPF patients, with a higher incidence rate compared to the general
population. These conditions may require a different management of the patient and a therapy
adjustment, and thus it is fundamental to recognize them. High Resolution Computed Tomography
(HRCT) is sensitive, but not specific, in detecting these complications, and can evaluate the presence of
radiological variations when previous examinations are available; it recognizes ground glass opacities
or consolidation that can be related to a large spectrum of comorbidities, such as infection, lung
cancer, or acute exacerbation. To reach the final diagnosis, a multidisciplinary discussion is required,
particularly when the clinical context is related to imaging findings.
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1. Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic and progressive interstitial lung disease with a
poor prognosis and a median survival rate of 2–3 years after diagnosis [1].
Several complications and comorbidities may occur in patients with IPF, sometimes with a
fatal outcome. These conditions include infection, malignancy, pulmonary hypertension, pulmonary
embolus, acute exacerbation, drug-induced pneumonitis, and cardiogenic pulmonary oedema [1–3].
High Resolution Computed Tomography (HRCT) is fundamental in diagnosing IPF, but also in
detecting these complications and comorbidities that can superimpose on the underlying disease.
In this review, we will discuss the imaging findings of the most common
parenchymal complications.
2. Imaging
According to the more recent guidelines of American Thoracic Society/European Respiratory
Society/ Japanese Respiratory Society/ Latin American Thoracic Association (ATS/ERS/JRS/ALAT) and
the Fleischner Society White Paper [4,5], high resolution computed tomography plays a central role in
the diagnosis of diffuse interstitial lung diseases, particularly in patients with a clinical suspect of IPF.
If a typical (Figure 1) or probable pattern of usual interstitial pneumonia (UIP) (Figure 2) is recognized
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on HRCT, in association with the appropriate clinical setting, the diagnosis of IPF can be made without
surgical biopsy.
Figure 1. Typical usual interstitial pneumonia (UIP) pattern on High Resolution Computed Tomography
(HRCT). Irregular inter- and intralobular septal thickening, with a subpleural, basal predominant.
Honeycombing, traction bronchiectasis, and bronchiolectasis are clearly seen in the basal region.
Figure 2. Probable UIP pattern on HRCT. Irregular inter- and intralobular septal thickening, with a
subpleural, basal predominant. Traction bronchiectasis and bronchiolectasis are seen in the fibrotic
areas. Honeycombing is not present.
Patients with IPF have a higher risk of comorbidities and lung cancer compared with the general
population [1].
HRCT has a role in establishing both acute and chronic parenchymal complications in patients
with IPF and, in particular, in detecting areas of parenchymal consolidation or ground glass opacities,
which can be an expression of infection, lung cancer, or acute exacerbation [6]. The differential diagnosis
among these conditions could be more easily made by the radiologist if clinical data and previous
Computed Tomography (CT) examination are available.
2.1. Infection
Patients with IPF may experience pulmonary infections with a higher frequency than patients
without IPF. Lung infections are the most frequently occurring comorbidity and are a common cause
of hospitalization [7]. It could be difficult to make a differential diagnosis with an acute exacerbation.
Some studies suggest that chronic viral infections may have a role in the pathogenesis of IPF, in
particular the Epstein–Barr virus and the latent human herpesvirus [8–10]. Moreover, the role of
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bacterial infections during infancy, especially from Staphylococcus and Streptococcus species, is being
investigated [11–13].
The most frequently observed pathogens are Mycobacterium species and Aspergillus species, along
with opportunistic infections such as Pneumocystis jirovecii [2]. The structural changes induced by
IPF in the lungs and the impairment of the local host immunity create a favorable environment
for mycobacterial colonization. Moreover, concomitant immunosuppressive therapies facilitate the
reactivation of tuberculosis [14]. Aspergillosis results from the saprophytic colonization of pre-existing
lung cavities.
Infections can be occasionally clearly diagnosed, as CT appearance is frequently non-specific,
and pre-existing background of parenchymal alterations may mask or alter the typical radiographical
pattern of these pathologies. An example can be given by the opportunistic infection of P. jirovecii, which
typically manifests on HRCT as bilateral, symmetric ground glass opacity, consolidation, and septal
thickening with a perihilar and upper lobe distribution and a subpleural lung sparing. Nevertheless, in
IPF P. jirovecii, infection can be undistinguishable from an acute exacerbation of IPF or the CT pattern,
showing no change compared to the previous examination, even in a clinical context of infection [2]
(Figure 3).
Figure 3. An example of Pneumocystis jirovecii pneumonia Broncho-Alveolar Lavage-confirmed. HRCT
demonstrated patchy areas of ground glass in the upper left lobe superimposed on a fibrotic background.
Tuberculosis has been reported to occur more frequently in IPF patients than the general
population [15,16]. A study by Shachor et al. found that the incidence of positive cultures for
Mycobacterium tuberculosis in chronic interstitial lung diseases was 4.5 times that of the general
population. In a study by Park et al. including 795 IPF patients, pulmonary infections with
Mycobacterium tuberculosis and nontuberculous mycobacterium were found in 35 (4.4%) and 16 (2.0%)
of patients, respectively. These rates were higher than those in the general population [14]. Patients
with IPF are more prone to develop Tuberculosis (TB) reactivation with HRCT, with a peripheral
mass-like lesion being shown to exist in more than half of patients, sometimes resembling lung cancer
in IPF (Figure 4), but sometimes presenting as subpleural nodules [15]. In 33% of cases, a segmental or
lobar coalescent consolidation with or without necrotizing cavitation may be observed, infrequently
associated with the typical TB reactivation patterns (patchy multifocal consolidation and centrolobular
nodules). It is mandatory to make a correct diagnosis to start an appropriate therapy.
Infections of Aspergillus species in IPF patients may result in the development of aspergilloma,
typically developing in pre-existing lung cavities or in a chronic airway invasive aspergillosis. CT
can effectively detect early changes, demonstrating the fungal fronds originating from the cavity wall
in early stages, with the subsequent detachment and coalescence of the cavity itself resulting in the
typical air crescent sign [2,17,18] (Figure 5).
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Figure 4. High Resolution Computed Tomography showing a nodule with spiculated margins, located
in the superior left lobe. The final diagnosis after pathological examination on the surgical specimen
demonstrated that it was a tuberculoma.
Figure 5. Figure courtesy of Carlo Florio. In a background of idiopathic pulmonary fibrosis, HRCT
showed the typical intracavitary mass with an adjacent “air crescent sign” due to Aspergillus infection.
In patients with IPF and bacterial infection, part-solid nodules (Figure 6) or ill-defined nodules
(Figure 7) may be seen. The same radiological findings can be present in lung cancer; therefore, in
some cases, a correct differential diagnosis is challenging. A Japanese cohort study found that, among
patients with IPF that require hospitalization, Gram-negative species are the most common pathogens
involved, in particular Haemophilus influenzae [19]. This is in contrast with community-acquired
infections, in which Gram-positive bacteria are more commonly isolated.
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Figure 6. HRCT from a patient with idiopathic pulmonary fibrosis, a current smoker. (a) A part-solid
nodule located in the upper right lobe, which, according to Fleischner Society, is highly suggestive of
lung cancer; (b) 3 month control after corticosteroid and antibiotic therapy showing complete resolution
of this opacity.
Figure 7. (a) A case of a patient with idiopathic pulmonary fibrosis with spiculated nodule; (b) the
control after corticosteroid and antibiotic therapy showing complete resolution of this opacity.
2.2. Lung Cancer
Patients with IPF have a five-fold increase of developing lung cancer when compared to the
general population [20,21], with an incidence rate of 11 cases per 100,000 persons per year. A large
meta-analysis estimated a rate of lung cancer prevalence in IPF patients of 13,54% [22]. Some risk
factors have been identified, such as age, male sex, and smoking history [22,23].
Both squamous cell carcinoma and adenocarcinoma have been observed, with a higher prevalence
of the former [24–26]. Moreover, IPF patients experience synchronous tumors with a higher prevalence
compared to non-IPF patients [27].
The pathogenesis remains unknown, and repeated episodes of cellular damage caused by
inflammatory mediators have been hypothesized. This cellular damage may cause genetic injury to the
respiratory epithelium, thus leading to cellular atypia, metaplasia, dysplasia, and finally carcinoma.
Considering the already poor survival rate of IPF patients, it is difficult to determine the impact of
the diagnosis of lung cancer on patients’ prognosis; moreover, papers reporting survival among IPF
patients with lung cancer are limited by small sample sizes [24,28,29]. A study by Ozawa et al. reported
a median survival time after lung cancer diagnosis in IPF of 13.1 months [20]. A retrospective analysis
of 632 patients with IPF found a 1 year all-cause mortality rate after lung cancer diagnosis of 53.5%,
confirming an overall poor survival [30].
On CT, lung cancer typically manifests as an ill-defined rounded lesion that can mimic an air-space
consolidation (Figure 8), or presents as a nodular lesion (Figure 9), making it difficult to distinguish
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from other entities. In most instances, lung cancer develops in fibrosis areas, typically within or abutted
areas of basal and peripheral honeycombing, with a typical prevalence for the lower lobes, compared
to the general population where it generally manifests in the upper lobes [31,32].
Figure 8. HRCT of a 70 year old man showing a consolidation area in the left upper lobe. Pathological
examination after biopsy detected an adenocarcinoma.
Figure 9. HRCT of a 63 year old man coming to the emergency room for an acute chest pain. HRCT
showed, in a background of pulmonary idiopathic fibrosis, pneumomediastinum, and pneumothorax,
a spiculated mass in the peripheral region of the left upper lobe due to squamous cell carcinoma.
Among invasive adenocarcinomas of the lung, invasive mucinous adenocarcinoma (previously
known as mucinous bronchoalveolar carcinoma) may appear on CT as a ground glass opacity, which
may have consolidative areas [33]. As shown in Figure 10, this pattern of CT presentation, in the context
of a fibrotic lung parenchyma, may mimic an inflammatory area, making a differential diagnosis
difficult. Therefore, a malignancy should always be considered as a possible diagnosis in case the
lesion does not respond to corticosteroid and antibiotic therapy.
In a CT scan, it could be difficult to distinguish areas of dense fibrosis from lung carcinoma
(Figure 11), thus a follow-up is required to evaluate the progression of this consolidation [34].
Analogous pattern on CT may be seen in pulmonary infarction and in TB reactivation. It has
been largely demonstrated in the literature that patients with IPF are more prone to suffer from acute
thromboembolism, thus developing pulmonary infarction [35,36]. Similar to cancer in IPF, pulmonary
infarction is mostly characterized by a peripheral and juxta pleural well-defined opacification without
air bronchograms, mostly developing in the lower lobes. The differential diagnosis is made even more
difficult by the clinical presentation, characterized by dyspnoea, tachypnea, and hypoxemia that can
mimic an acute exacerbation of IPF [37,38].
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Figure 10. Figure courtesy of Roberta Polverosi. A well-defined ground glass opacity within a
fibrosis area in the right lower lobe, persistent after corticosteroid and antibiotic therapy. The biopsy
demonstrated a mucinous bronchioloalveolar carcinoma.
Figure 11. (a) HRCT showing a small ill-defined opacity in the upper left lobe of uncertain etiology; (b)
the nodule remaining stable at the control HRCT after 3 years.
2.3. Acute Exacerbation
IPF is a progressive and chronic disease with a course that can be unpredictable. Indeed, some
patients may manifest a slow and progressive deterioration of lung function, while others may present
a rapid progression with a fast decline of the clinical conditions. In some cases, episodes of sudden
worsening of symptoms and lung function can occur. These cases are defined as acute exacerbation
(AE-IPF).
The revised definition of acute exacerbation of IPF is an acute, clinically significant, respiratory
deterioration characterized by evidence of new, widespread alveolar abnormality [39]. It seriously
worsens life expectancy, with up to 50% of patients dying during the acute event, and a significant
decrease in short-term survival of three to four months after the episode [40–46]. Moreover, if the
patient needs mechanical ventilation, the mortality rate increases to 90% of cases [47].
Although the pathogenesis of acute exacerbations is still unknown, it is thought to share some
similarities with acute lung injury (ALI), in which a diffuse alveolar damage (DAD) occurs secondary
to an acute event, such as viral infections, gastro oesophageal reflux (GER), surgical lung biopsy
or resection, immunosuppressive therapy, bronchoalveolar lavage, or any mechanical procedure
(Figure 12).
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Figure 12. HRCT showing a rapid worsening of reticular abnormalities after a Computed
Tomography-guided biopsy of a basal rounded mass.
It has also been observed that episodes are more frequent in patients with a physiologically
and functionally advanced disease, in combination with a more progressive disease [48], in
wintertime [46,49,50], in young people, in patients with coronary artery disease, in cardiogenic
pulmonary oedema, and in those with a high body mass index.
The criteria to define AE-IPF are a previous or concurrent diagnosis of IPF, an unexplained
worsening or development of dyspnoea within 30 days, and exclusion of alternative causes (left heart
failure) [51].
On HRCT, it manifests with new bilateral ground glass abnormality and/or consolidation
superimposed on a background reticular or honeycombing (Figure 13) [52]. It has been noticed that the
pattern and extent of opacification can be related to the clinical outcome, observing that patients with a
diffuse pattern have a higher risk of death compared to those with a peripheral one. If an asymmetrical
distribution of the opacification (consolidation or ground glass) is seen on HRCT, this is a predictor of
a better outcome in patients with AE-IPF [53].
HRCT is sensitive, but not specific, in recognizing AE-IPF, since other conditions may present
a diffuse increase in attenuation of the lung parenchyma in a background of pre-existing fibrosis,
and thus these must be taken into account in differential diagnosis. These conditions are pulmonary
infections, drug-induced pneumonias, and pulmonary oedema due to heart failure.
In particular, if pleural effusion or profuse septal thickening (an uncommon feature in
non-complicated IPF) are associated with the ground glass opacities, heart failure should be highly
suspected [2]. Along with pathological conditions, even some technical factors during exam acquisition
can determine spurious increased opacification, such as scan acquisition at the end of expiration or
intravenous contrast administration [2].
A list of the main parenchymal complications occurring during IPF with their CT scan
characteristics is presented in Table 1.
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Figure 13. HRCT of an IPF patient with acute deterioration of symptoms and lung function, compared
to the baseline HRCT. (a,b) A rapid and progressive development of diffuse and symmetric ground
glass opacities; (c,d) suggestive of an acute exacerbation. The patient died 3 weeks after.
Table 1. Classification of lung parenchymal complications in patients with idiopathic pulmonary
fibrosis (IPF) and HRCT features.
Acute/Chronic Complication HRCT Features
Acute
Infections
Mycobacterium species
Peripheral mass-like lesion/subpleural
nodules/segmental or lobar coalescent consolidation
with or without necrotising cavitation.
Pneumocystis jirovecii Ground glass opacity/no change from the baseline in aclinic context of infection.
Aspergillus Fungal fronds in a pre-existing cavity in early stages.Subsequent coalescence of the cavity (air crescent sign).
Acute exacerbation IPF
New bilateral ground glass opacities and/or
consolidation on a background of reticular or
honeycombing pattern.
Right heart failure
Profuse septal thickening, ground glass opacities,
pleural effusion on a background of reticular or
honeycombing pattern.
Chronic Lung cancer
Ill-defined rounded lesion, mimicking air space
consolidation/nodular lesion developing within
peripheral and basal honeycombing areas.
Ground glass opacity in fibrosis area (mucinous
bronchioloalveolar carcinoma).
If a clinical suspect of AE-IPF is present, to reach the final diagnosis a multidisciplinary discussion
is required.
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3. Conclusions
HRCT has an increasingly predominant role in the diagnosis of IPF. Moreover HRCT plays a
fundamental role in detecting IPF in both acute and chronic parenchymal complications that can
seriously worsen the clinical course.
Besides lung cancer, patients with IPF can develop opacities, including inflammatory
consolidations, areas of dense fibrosis, infarction due to pulmonary embolism, or acute exacerbation.
Clinical presentation plays a crucial role for a correct interpretation of CT findings.
It is important to identify these opacities, particularly through involving an expert thoracic
radiologist who can better evaluate the radiological aspects and make a comparison with previous
radiological examinations when available.
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